Go to deals
Healthcare

Shield Therapeutics has raised funds

Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.

Shield is a de-risked, specialty pharmaceutical company focused on commercializing its lead product, Feraccru®/Accrufer®, a novel, non-salt-based oral therapy for adults with iron deficiency with or without anemia.

Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as the joint broker on this transaction.

Service
Funding, debt advisory & ECM
Parties

Talk to the deal team

 Geoff  Nash

Geoff Nash

Partner

London, United Kingdom
Oaklins Cavendish

Related deals

Gilde Healthcare has invested in Tandarts Today
Private Equity | Healthcare

Gilde Healthcare has invested in Tandarts Today

Gilde Healthcare has invested in Tandarts Today, a fast-growing dental chain in the Netherlands. The investment will allow Tandarts Today to accelerate its buy-and-build strategy and become a leading dental chain in the Netherlands. Financial details have not been disclosed.

Learn more
Avantium has raised US$33.6m via an accelerated bookbuild offering
Other Industries

Avantium has raised US$33.6m via an accelerated bookbuild offering

Avantium N.V. has raised US$33.6 million through an accelerated bookbuild offering of 5,206,589 new ordinary shares, representing approximately 19.99% of the company’s issued share capital. The shares have been placed at a price of US$6.42 (€5.35) per new ordinary share.

Learn more
Alcidion (ASX:ALC) has completed a capital raise
Healthcare

Alcidion (ASX:ALC) has completed a capital raise

Alcidion (ASX:ALC) has raised funds to continue its growth strategy.

Learn more